1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Panchsheel Organics Limited

Panchsheel Organics Limited

BBSE:PANCHSHEEL
96.90
INR
-6.15
(-5.97%)
7.82EPS
15.09P/E
1.55BMarket Cap
Panchsheel Organics Limited
BSE:PANCHSHEEL
(Bombay Stock Exchange)

Recent

price

96.90

P/E

ratio

15.09

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
26.3
29.83
33.3
39.06
35.69
40.27
37.76
40.8
48.08
50.23
97.72
68.8
93.27
79.87
81.3
80.99
81.86
Revenue per Share
0.7
1.81
1.26
1.75
1.89
3.03
3.2
3.66
4.02
5.27
9.98
8.33
12.78
10.71
10.47
8.22
7.82
Basic EPS, GAAP
1.22
0.14
-0.71
2.24
-0.12
-0.28
-0.71
2.27
1.48
4.07
6.19
-3.27
-3.55
-0.25
-8.9
2.58
- -
Free Cash Flow per Basic Share
- -
- -
- -
0.04
0.29
0.6
0.45
0.4
0.47
0.49
1.28
0.66
3.21
2.68
3
3.2
- -
Dividend per Share
13.72
15.53
15.98
17.45
18.45
21.18
23.77
26.89
30.39
35.2
39.56
47.26
81.54
94.93
101.63
135.61
- -
Book Value per Share
13.72
15.53
15.98
17.45
18.45
21.18
23.77
26.89
30.39
35.2
39.56
47.26
81.54
94.93
101.63
135.61
- -
Tangible Book Value per Share
10
10
10
10
10
10
10
10
10
10
5
10
11
13
13
13
13
Basic Weighted Avg Shares
264
299
334
392
358
404
379
409
482
504
490
690
1,027
1,052
1,071
1,067
1,078
Sales/Revenue/Turnover
7.06
10.36
7.12
8.61
13.86
11.16
14.43
14.32
12.35
15.7
16.05
16.81
17.8
16.37
14.38
10.52
9.86
Operating Margin (%)
4
5
10
11
15
13
12
12
12
11
11
12
16
17
22
23
24
Depreciation Expense
7
18
13
18
19
30
32
37
40
53
50
84
141
141
138
108
103
Net Income, GAAP
51.7
29.5
28.16
34.77
31.28
27.23
36.01
29.17
28.65
27.65
31.37
26.67
26.22
27.24
23.77
25.14
25.33
Effective Tax Rate (%)
2.68
6.07
3.79
4.49
5.3
7.53
8.48
8.98
8.37
10.5
10.21
12.11
13.7
13.41
12.88
10.15
9.55
Profit Margin (%)
99
117
103
118
148
150
154
177
210
250
271
383
525
733
645
632
- -
Working Capital
26
21
5
6
21
15
10
6
1
- -
10
10
5
3
2
1
- -
LT Debt
138
156
160
175
185
212
238
270
305
353
397
474
961
1,250
1,339
1,408
- -
Total Equity
3.87
8.75
5.84
7.89
7.96
11.95
10.74
12.18
11.82
14.21
12.16
17.56
17.5
10.71
8.67
5.87
- -
Return on Invested Capital (%)
3.87
8.75
5.84
9.85
9.7
13.23
12.19
12.59
12.33
14.39
12.4
17.68
18.54
12.17
10.24
7.64
- -
Return on Capital (%)
5.28
12.37
8.01
10.49
10.55
15.3
14.24
14.46
14.05
16.08
13.35
19.19
19.61
12.76
10.66
7.89
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
56
- -
LT Borrowings
- -
1
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
10
13
Market Capitalization
1,711
937
1,554

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
895
- -
Cash, Cash Equivalents & STI
- -
38
- -
Accounts Receivable, Net
- -
392
- -
Inventories
- -
451
- -
Total Current Liabilities
- -
264
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
56
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
23.11%
32.9%
5.21%
Free Cash Flow
295.74%
621.95%
-128.99%
Net Income, GAAP
16.75%
22.37%
-21.49%
Sales/Revenue/Turnover
11.49%
18.7%
-0.38%
Total Cash Common Dividend
46.91%
90.61%
6.56%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
261
272
262
284
1,071
2026
236
253
267
311
1,067
2027
247
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2.6
2.88
2.79
2.41
10.47
2026
2.16
1.98
2.79
1.29
8.22
2027
1.76
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
3
2026
- -
- -
- -
- -
3.2
2027
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Panchsheel Organics Limited, founded in 1989 and headquartered in Mumbai with manufacturing facilities in Indore, Madhya Pradesh, manufactures and exports active pharmaceutical ingredients, intermediates, finished formulations for human and veterinary use; nutraceuticals; vitamins, hormones, and steroids; agri biotech products including biofertilizers, biostimulants, and growth promoters; aquaculture products; dehydrated culture media; probiotics and enzymes; micro pellets, direct compression granules, and sustained/modified release pellets; as well as specialty chemicals such as insecticides, herbicides, pesticides, fungicides, viricides, water-soluble fertilizers, and plant growth regulators. The company operates primarily from India with exports to international markets and offers custom synthesis, contract manufacturing, and job work for APIs, drug intermediates, and formulations; its product portfolio spans categories like cardiovascular, neuropsychiatry, antifungal, fluoroquinolones, antiallergic, anti-inflammatory, gastrointestinal, oncology, over-the-counter remedies, and animal health supplements. In recent developments, Panchsheel Organics allotted equity shares on a preferential basis in September 2022 to fund Phase 1 capex of Rs 40 crore at Pithampur and Indore for probiotics and enzymes production with 36-40 TPA capacity targeting Rs 40-50 crore revenue by FY25; it is advancing Phase 2 capex of Rs 50-70 crore at DMIC Vikram Udyogpuri Biotech Park for fermentation-based and API pharmaceuticals adding 36-40 TPA fermentation and 120 TPA API capacity; the board declared an interim dividend for the quarter ended June 30, 2025 in August 2025 and continues reporting steady financial results including unaudited quarterly outcomes through September 2025.